$ADVM
Adverum Biotechnologies, Inc. Stock $advm

$advm Overview Financials Valuation SEC Filings Company Website

2020 Q3 Form 10-K Financial Statement

#000162828021003623 Filed on March 01, 2021

Income Statement

Concept	2020 Q3	2020	2019 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.35M	$44.64M	$8.280M
YoY Change	53.59%	57.29%	59.54%
% of Gross Profit
Research & Development	$16.65M	$73.31M	$11.37M
YoY Change	67.47%	81.37%	-2.32%
% of Gross Profit
Depreciation & Amortization	$1.180M	$4.160M	$350.0K
YoY Change	218.92%	164.97%	-10.26%
% of Gross Profit
Operating Expenses	$28.00M	$118.0M	$19.65M
YoY Change	61.56%	71.45%	16.76%
Operating Profit	-$28.00M	-$118.0M
YoY Change	63.93%	72.08%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$235.0K	$1.557M	$730.0K
YoY Change	-75.65%	-61.64%	-33.64%
Pretax Income	-$27.77M	-$116.4M	-$18.93M
YoY Change	72.27%	80.49%	20.88%
Income Tax		$1.114M	$0.00
% Of Pretax Income
Net Earnings	-$27.77M	-$117.5M	-$18.93M
YoY Change	72.29%	82.22%	20.89%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.31	-$1.38
Diluted Earnings Per Share	-$0.31	-$1.38	-$290.7K
COMMON SHARES
Basic Shares Outstanding	88.87M shares	85.15M shares
Diluted Shares Outstanding	88.87M shares	85.15M shares

Balance Sheet

Concept	2020 Q3	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$454.5M	$429.7M	$166.0M
YoY Change	180.56%	158.86%	-19.06%
Cash & Equivalents	$72.70M	$62.40M	$65.90M
Short-Term Investments	$381.8M	$367.3M	$100.1M
Other Short-Term Assets	$5.200M	$4.700M	$9.800M
YoY Change	-7.14%	-52.04%	164.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$459.7M	$434.4M	$175.9M
YoY Change	174.28%	146.96%	-15.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$27.30M	$47.10M	$24.88M
YoY Change	79.0%	2.84%	593.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$19.00K	$1.000M	$11.00K
YoY Change	-88.41%	0.0%	-92.95%
Total Long-Term Assets	$48.01M	$48.20M	$46.86M
YoY Change	26.6%	2.99%	888.34%
TOTAL ASSETS
Total Short-Term Assets	$459.7M	$434.4M	$175.9M
Total Long-Term Assets	$48.01M	$48.20M	$46.86M
Total Assets	$507.7M	$482.6M	$222.7M
YoY Change	147.03%	116.7%	4.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.034M	$2.800M	$4.103M
YoY Change	-10.29%	-31.71%	140.36%
Accrued Expenses	$13.10M	$18.10M	$15.30M
YoY Change	-9.03%	18.3%	73.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.11M	$20.90M	$19.41M
YoY Change	-9.21%	7.73%	81.06%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$136.0K	$27.30M	$148.0K
YoY Change	-26.49%	-3.87%	-39.09%
Total Long-Term Liabilities	$136.0K	$27.30M	$148.0K
YoY Change	-26.49%	-3.87%	-39.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.11M	$20.90M	$19.41M
Total Long-Term Liabilities	$136.0K	$27.30M	$148.0K
Total Liabilities	$43.00M	$48.20M	$47.77M
YoY Change	4.09%	0.84%	287.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$464.9M		-$385.0M
YoY Change	26.99%		20.12%
Common Stock	$930.2M		$560.7M
YoY Change	75.16%		7.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$464.7M	$434.3M	$175.0M
YoY Change
Total Liabilities & Shareholders Equity	$507.7M	$482.6M	$222.7M
YoY Change	147.03%	116.7%	4.32%

Cashflow Statement

Concept	2020 Q3	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$27.77M	-$117.5M	-$18.93M
YoY Change	72.29%	82.22%	20.89%
Depreciation, Depletion And Amortization	$1.180M	$4.160M	$350.0K
YoY Change	218.92%	164.97%	-10.26%
Cash From Operating Activities	-$26.55M	-$79.29M	-$14.83M
YoY Change	178.59%	61.26%	16.5%
INVESTING ACTIVITIES
Capital Expenditures	-$3.080M	$11.84M	-$8.380M
YoY Change	-50.24%	-38.46%	5137.5%
Acquisitions
YoY Change
Other Investing Activities	-$129.3M	-$268.3M	-$10.84M
YoY Change	1364.21%	449.5%	-232.52%
Cash From Investing Activities	-$132.4M	-$280.2M	-$19.21M
YoY Change	781.88%	311.57%	-339.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$200.0K	$344.3M
YoY Change		1236.84%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	204.3M	$356.0M	26.77M
YoY Change	-227044.44%	1162.76%	-133950.0%
NET CHANGE
Cash From Operating Activities	-26.55M	-$79.29M	-14.83M
Cash From Investing Activities	-132.4M	-$280.2M	-19.21M
Cash From Financing Activities	204.3M	$356.0M	26.77M
Net Change In Cash	45.33M	-$3.473M	-7.270M
YoY Change	-284.04%	-96.1%	53.7%
FREE CASH FLOW
Cash From Operating Activities	-$26.55M	-$79.29M	-$14.83M
Capital Expenditures	-$3.080M	$11.84M	-$8.380M
Free Cash Flow	-$23.47M	-$91.14M	-$6.450M
YoY Change	602.69%	33.21%	-48.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001501756
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-36579
CY2020	dei	Entity Registrant Name EntityRegistrantName	Adverum Biotechnologies, Inc.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5258327
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	800 Saginaw Drive
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94063
CY2020	dei	City Area Code CityAreaCode	650
CY2020	dei	Local Phone Number LocalPhoneNumber	656-9323
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2020	dei	Trading Symbol TradingSymbol	ADVM
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	1500000000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	97796128	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62424000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65897000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	367305000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	100138000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4709000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9835000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	434438000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	175870000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19376000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20963000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27725000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24884000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	999000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	999000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11000	USD
CY2020Q4	us-gaap	Assets Assets	482567000	USD
CY2019Q4	us-gaap	Assets Assets	222727000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2810000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4103000	USD
CY2020Q4	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	13588000	USD
CY2019Q4	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	11271000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4473000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4034000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20871000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19408000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26235000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28214000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1114000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	148000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	48220000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	47770000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	97549000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	97549000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67329000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67329000	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	937134000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	560704000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-261000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-725000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-502536000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-385029000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	434347000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	174957000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	482567000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	222727000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	250000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1612000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	73309000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40419000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50133000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	44641000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28376000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24560000	USD
CY2020	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2019	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2018	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	5000000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	117950000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	68795000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	79693000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-117950000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-68545000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-78081000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1557000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4059000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4204000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-116393000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64486000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-73877000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1114000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1250000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-64486000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-72627000	USD
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	93000	USD
CY2019	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	33000	USD
CY2018	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	168000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	-342000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	29000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	41000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-4000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-117043000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-64412000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-72463000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.38
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.01
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.18
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85146000	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	64102000	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	61375000	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	184028000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4140000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70187000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13432000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	688000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	340000	USD
CY2018	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1191000	USD
CY2018	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	168000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-4000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-72627000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	201167000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1065000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25755000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9899000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3442000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	442000	USD
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1470000	USD
CY2019	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	33000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	41000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-64486000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	174957000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	676000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	344298000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20391000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12687000	USD
CY2020	advm	Warrants Issued During Period Shares WarrantsIssuedDuringPeriodShares	36000	shares
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1100000	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2043000	USD
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	93000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	-342000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	29000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-117507000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	434347000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-64486000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-72627000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4158000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1573000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1750000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	20391000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	9899000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	13432000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-521000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1273000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-24000	USD
CY2020	us-gaap	Accretion Expense AccretionExpense	17000	USD
CY2019	us-gaap	Accretion Expense AccretionExpense	22000	USD
CY2018	us-gaap	Accretion Expense AccretionExpense	95000	USD
CY2020	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2019	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2018	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	5000000	USD
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-342000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-58000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-36000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	17000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-5854000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5954000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	793000	USD
CY2020	advm	Increase Decrease In Deposit And Other Noncurrent Assets IncreaseDecreaseInDepositAndOtherNoncurrentAssets	18000	USD
CY2019	advm	Increase Decrease In Deposit And Other Noncurrent Assets IncreaseDecreaseInDepositAndOtherNoncurrentAssets	0	USD
CY2018	advm	Increase Decrease In Deposit And Other Noncurrent Assets IncreaseDecreaseInDepositAndOtherNoncurrentAssets	16000	USD
CY2020	advm	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	1587000	USD
CY2019	advm	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	2168000	USD
CY2018	advm	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1585000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-650000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-67000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4147000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1909000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	215000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2019	us-gaap	Straight Line Rent StraightLineRent	0	USD
CY2018	us-gaap	Straight Line Rent StraightLineRent	-1243000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1114000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-953000	USD
CY2020	us-gaap	Straight Line Rent StraightLineRent	0	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2020	advm	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1540000	USD
CY2019	advm	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	7586000	USD
CY2018	advm	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	0	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
CY2019	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	0	USD
CY2018	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1250000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-79291000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-49170000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53964000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	570386000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	197343000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	78726000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	295315000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	148517000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	148979000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6748000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11844000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19247000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	809000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-280167000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-68073000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	69444000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	344302000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25755000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	70187000	USD
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	134000	USD
CY2018	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12687000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3442000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	688000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2043000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1470000	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1191000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	1100000	USD
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	442000	USD
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	340000	USD
CY2020	us-gaap	Repayments Of Debt RepaymentsOfDebt	61000	USD
CY2019	us-gaap	Repayments Of Debt RepaymentsOfDebt	112000	USD
CY2018	us-gaap	Repayments Of Debt RepaymentsOfDebt	175000	USD
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	100000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	355985000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28191000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	69949000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3473000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-89052000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	85429000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	66896000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	155948000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	70519000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	63423000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	66896000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	155948000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	403000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5242000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1616000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-502500000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, fair values of financial instruments, and incremental borrowing rate. The Company’s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company’s original estimates in any periods presented.</span>
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—Financial instruments that potentially subject the Company to significant concentrations of credit risk consists primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company’s investment policy, which limits the Company’s investing to only those marketable securities rated at least A-1/P-1 Short Term Rating and A/A2 Long Term Rating, as determined by independent credit rating agencies. Management believes that the Company is not exposed to significant credit risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company’s ability to attract and retain employees necessary to support the growth.</span></div>
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	367191000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	121000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	367305000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	100117000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	28000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	7000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	100138000	USD
CY2020Q4	advm	Other Than Temporary Impaired Investments Available For Sale Securities OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities	0	USD
CY2020Q4	advm	Debt Securities Available For Sale Maturity Allocated And Single Maturity Date After One Through Two Years DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears	21000000.0	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4683000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	4846000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5016000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5191000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	5800000	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	6500000	USD
CY2018	us-gaap	Operating Lease Expense OperatingLeaseExpense	3300000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	1500000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	1600000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4200000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5373000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	18273000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1600000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	43382000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12674000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27725000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24884000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	30708000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	37797000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	32876000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10072000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7992000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1800000	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	8344000	USD
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	4055000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1075000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2607000	USD
CY2020Q4	advm	Accrued Preclinical Costs Current AccruedPreclinicalCostsCurrent	1824000	USD
CY2019Q4	advm	Accrued Preclinical Costs Current AccruedPreclinicalCostsCurrent	1002000	USD
CY2020Q4	advm	Accrued Clinical And Development Process Costs Current AccruedClinicalAndDevelopmentProcessCostsCurrent	1020000	USD
CY2019Q4	advm	Accrued Clinical And Development Process Costs Current AccruedClinicalAndDevelopmentProcessCostsCurrent	971000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1325000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2636000	USD
CY2020Q4	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	13588000	USD
CY2019Q4	advm	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	11271000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	0	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	90000	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.77
CY2020	advm	Class Of Warrant Or Right Net Exercise Of Warrants ClassOfWarrantOrRightNetExerciseOfWarrants	50000	shares
CY2020	advm	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Net Exercises ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsNetExercises	3.79
CY2020	advm	Class Of Warrant Or Right Expiry Of Warrants ClassOfWarrantOrRightExpiryOfWarrants	40000	shares
CY2020	advm	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Expiry Of Warrants ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExpiryOfWarrants	10.51
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.94
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2020	advm	Class Of Warrant Or Right Expiry Of Warrants ClassOfWarrantOrRightExpiryOfWarrants	40000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6695000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.51
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	9539000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2049000	shares
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1606000	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.43
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	691000	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.90
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6447000	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.83
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3594000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4978000	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.16
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1397000	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.46
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1033000	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.93
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8995000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.19
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	48073000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4126000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	18.52
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2043000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.21
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	646000	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.67
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3903000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.82
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10432000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.65
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	31626000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	10432000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	11.65
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y2M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	31626000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	19722000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	20800000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10700000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8200000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.39
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.04
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.15
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	54900000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2020	advm	Income Tax Reconciliation Change In State Uncertain Tax Position IncomeTaxReconciliationChangeInStateUncertainTaxPosition	2305000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20391000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9899000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13432000	USD
CY2020	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	300000	USD
CY2019	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1200000	USD
CY2018	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	4100000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	700000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1114000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1114000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1250000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1250000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1114000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-13542000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15514000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2787000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1250000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-110327000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-59426000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-45024000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-6066000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-5060000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-28853000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-116393000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64486000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-73877000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-24442000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	41000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	24817000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	18312000	USD
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-586000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Restructuring Charges IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges	2669000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1212000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1512000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	941000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	307000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	75000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	166000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	298000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3150000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	948000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1215000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11219000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	595000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-212000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Restructuring Charges IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges	0	USD
CY2019	advm	Income Tax Reconciliation Change In State Uncertain Tax Position IncomeTaxReconciliationChangeInStateUncertainTaxPosition	-6242000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Restructuring Charges IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	11727000	USD
CY2018	advm	Income Tax Reconciliation Change In State Uncertain Tax Position IncomeTaxReconciliationChangeInStateUncertainTaxPosition	6242000	USD
CY2020	advm	Income Tax Reconciliation State Deferred Tax Adjustment IncomeTaxReconciliationStateDeferredTaxAdjustment	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2000	USD
CY2019	advm	Income Tax Reconciliation State Deferred Tax Adjustment IncomeTaxReconciliationStateDeferredTaxAdjustment	3239000	USD
CY2018	advm	Income Tax Reconciliation State Deferred Tax Adjustment IncomeTaxReconciliationStateDeferredTaxAdjustment	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1114000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1250000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	151000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	74023000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	53309000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1588000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	834000	USD
CY2020Q4	advm	Deferred Tax Assets Lease Obligation DeferredTaxAssetsLeaseObligation	6630000	USD
CY2019Q4	advm	Deferred Tax Assets Lease Obligation DeferredTaxAssetsLeaseObligation	6896000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	4483000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6008000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5975000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4767000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	18000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	24000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	99963000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	71989000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	94645000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66201000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5318000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5788000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	4183000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2745000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	18900000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8700000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3558000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8805000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1135000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1305000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5318000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5788000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	28400000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3600000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8800000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3558000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8805000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	257000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	995000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4119000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8677000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	6242000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1941000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5119000	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10998000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10221000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8996000	shares
CY2020Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	200000	USD

Files In Submission

Name	View Source	Status
0001628280-21-003623-index-headers.html	Edgar Link	pending
0001628280-21-003623-index.html	Edgar Link	pending
0001628280-21-003623.txt	Edgar Link	pending
0001628280-21-003623-xbrl.zip	Edgar Link	pending
advm-20201231.htm	Edgar Link	pending
advm-20201231.xsd	Edgar Link	pending
advm-20201231xexx211.htm	Edgar Link	pending
advm-20201231xexx231.htm	Edgar Link	pending
advm-20201231xexx311.htm	Edgar Link	pending
advm-20201231xexx312.htm	Edgar Link	pending
advm-20201231xexx321.htm	Edgar Link	pending
advm-20201231xexx322.htm	Edgar Link	pending
advm-20201231xexx42.htm	Edgar Link	pending
advm-20201231_cal.xml	Edgar Link	unprocessable
advm-20201231_def.xml	Edgar Link	unprocessable
advm-20201231_g1.jpg	Edgar Link	pending
advm-20201231_g2.jpg	Edgar Link	pending
advm-20201231_g3.jpg	Edgar Link	pending
advm-20201231_g4.jpg	Edgar Link	pending
advm-20201231_g5.jpg	Edgar Link	pending
advm-20201231_htm.xml	Edgar Link	completed
advm-20201231_lab.xml	Edgar Link	unprocessable
advm-20201231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADVM
Adverum Biotechnologies, Inc. Stock $advm

2020 Q3 Form 10-K Financial Statement

#000162828021003623 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADVM Adverum Biotechnologies, Inc. Stock $advm

2020 Q3 Form 10-K Financial Statement

#000162828021003623 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADVM
Adverum Biotechnologies, Inc. Stock $advm